v3.26.1
Business Combination (Tables)
 6 Months Ended
Mar. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Summary of Purchase Price he purchase price as set forth below (in thousands):
Purchase PriceFair Value
Cash paid at closing$14,455 
Transaction bonus paid on March 27, 20261,329 
Preexisting contractual liability settlement13,841 
Transaction expenses133 
Contingent consideration2,483 
$32,241 
UK Biocentre cash balance at closing
$4,767 
Purchase price, net of cash acquired$27,474 
Cash paid, net of cash acquired$11,017 
Summary of Tangible and Intangible Assets Acquired and Liabilities Assumed
The purchase price was allocated to UK Biocentre’s tangible and identifiable intangible assets acquired and liabilities assumed based on the estimated fair values as of March 4, 2026, as set forth below (in thousands):

Purchase Price Allocation Fair Value
Accounts Receivable$2,053 
Inventory846 
Other assets795 
Operating lease right-of-use assets3,176 
Property and Equipment22,263 
Identifiable Intangible Assets:
Trademarks1,039 
Accounts Payable(930)
Accruals(3,708)
Operating lease liabilities(3,176)
Goodwill5,116 
Total purchase price, net of cash acquired$27,474